Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates
about
Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus IsolatesRelationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infectionsCharacterization of methicillin-resistant Staphylococcus aureus isolates from patients with persistent or recurrent bacteremia.Observation of "seesaw effect" with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains.Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections.Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus.Persistent catheter-related Staphylococcus aureus bacteremia after catheter removal and initiation of antimicrobial therapy.Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTURE.Reduced vancomycin susceptibility found in methicillin-resistant and methicillin-sensitive Staphylococcus aureus clinical isolates in Northeast China.Epidemiology and outcome of pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) in Canadian hospitalsVancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey.Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections.Clinical and microbiologic analysis of the risk factors for mortality in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia.Ceftaroline in complicated skin and skin-structure infections.High prevalence of isolates with reduced glycopeptide susceptibility in persistent or recurrent bloodstream infections due to methicillin-resistant Staphylococcus aureus.Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care unitsRapid Detection of Vancomycin-Intermediate Staphylococcus aureus by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry.Predictors of mortality in Staphylococcus aureus BacteremiaDaptomycin and tigecycline have broader effective dose ranges than vancomycin as prophylaxis against a Staphylococcus aureus surgical implant infection in miceClinical and Microbiological Characteristics of Heteroresistant and Vancomycin-Intermediate Staphylococcus aureus from Bloodstream Infections in a Brazilian Teaching HospitalHeteroresistant Vancomycin Intermediate Coagulase Negative Staphylococcus in the NICU: A Systematic Review.A Novel Microfluidic Assay for Rapid Phenotypic Antibiotic Susceptibility Testing of Bacteria Detected in Clinical Blood Cultures.Staphylococcus aureus with reduced susceptibility to vancomycin in healthcare settings.Mortality predictors of Staphylococcus aureus bacteremia: a prospective multicenter studyPrevalence and Clinical Impact of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolated From Hospitalized Patients.Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus: Does Vancomycin Heteroresistance Matter?Accessory gene regulator (agr) dysfunction in Staphylococcus aureus bloodstream isolates from South Korean patients.Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections?Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream InfectionMolecular Epidemiology of a Vancomycin-Intermediate Heteroresistant Staphylococcus epidermidis Outbreak in a Neonatal Intensive Care Unit.Activities of vancomycin, ceftaroline, and mupirocin against Staphylococcus aureus isolates collected in a 2011 national surveillance study in the United States.Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy.MRSA: the first half century.The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.Vancomycin therapeutics and monitoring: a contemporary approach.Multidrug-resistant organisms in dialysis patients.Methicillin-resistant Staphylococcus aureus: an evolving pathogen.Glycopeptide antibiotics: back to the future.Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus.Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.
P2860
Q26796560-BFADA362-DF71-44DB-BA70-431BCD74ACB1Q27011138-005F511D-16EB-4496-8BEA-25E445648491Q33640218-A3F4D867-B8A8-4F94-B0C3-7787BEF52D5DQ33939095-89B0672D-AC88-4EEE-8505-2F00187B1BF9Q33945397-41326383-B936-45C4-B03D-442EAFFFA5EEQ34058222-6B5D823A-3AC3-4A69-98B9-BE88C1108996Q34463444-C84CA28C-C3B5-4586-A8BD-734A34F80974Q34726283-9A13BD7D-0BF4-4648-9ECD-9F86C2629C2EQ34998629-6EA50521-163B-460B-B623-DDABCD53702AQ34999500-7D101898-49A6-4B10-ABA5-95B622F271E5Q35064413-773DC937-A020-432A-8E94-3E5A155557B0Q35169018-E6A0C8D9-2CB9-4B52-93F3-A0CE9F192C90Q35607912-D457824E-2E84-446C-B274-59A1C2667A8FQ35715381-69F0344F-93D1-414A-9D2F-58A4CFE0AC79Q35806306-6A330874-A230-470F-88C4-5E61E2A472CEQ35819831-6C5CFE95-13AA-48F4-A610-9588E031747AQ35893439-7D2E6DE3-ADC4-4CE0-9809-7511A9874767Q35940556-9F52D9B9-9E51-4D7E-A95F-97C42B3C4A6DQ35941476-E8D24CC2-5F8E-4A2E-9869-C8AE740E84F6Q36116970-0D2F9833-D9C1-4C22-A7DF-066C99A6AC27Q36157736-008CE794-CBC5-4EC6-8049-1030F34C8E8EQ36224227-8FEC43FA-B095-446C-B7AE-2C23D9F036ECQ36478309-DC344D45-FE50-4643-9DEE-419378604E77Q36565826-F0D5AF8E-6E9C-47AD-A670-0C447FE932B6Q36636699-B500B2A3-CF2B-4AF8-9CF4-FEA231B700F1Q36644689-A296FA8D-824F-4EA1-AB68-67E1CAC60E77Q36667182-F63CE46C-CA31-4B07-ADB5-3A8EDFC0615CQ36856946-422BA28E-9B00-4505-A5C9-626BEF575EF8Q37124131-8312BF47-2BEA-4A7A-ACE6-FACD37CABAB6Q37287797-979D0B8C-9DD0-4BF5-B2E6-FEF4CEC30991Q37544625-61759379-9B42-4020-9C34-9DFE40A67922Q37713010-9AB1FC44-3BD6-4008-A839-2697D3CDAC13Q37947249-D6EC9251-343E-4DD9-ACB8-CFE037A139F5Q37981103-44D25A93-2599-4796-8AEB-6FB8E780C1BCQ38062923-A25721BD-58A0-4D0D-9CEE-BA9F848F50A4Q38102740-1DE37227-223B-4CFA-B5B9-D03A68041441Q38171759-EF3FA777-55BA-4587-BBEE-785FE9328EFBQ38239460-FCF27398-3ECA-44C4-9E4B-2E01EBDC6233Q38425879-5E3657F7-3984-420F-B63A-D90BA389450AQ38428770-7499A7F9-A0BD-4B17-B562-7C7BC81A172C
P2860
Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Systematic review and meta-ana ...... Staphylococcus aureus isolates
@en
Systematic review and meta-ana ...... taphylococcus aureus isolates.
@nl
type
label
Systematic review and meta-ana ...... Staphylococcus aureus isolates
@en
Systematic review and meta-ana ...... taphylococcus aureus isolates.
@nl
prefLabel
Systematic review and meta-ana ...... Staphylococcus aureus isolates
@en
Systematic review and meta-ana ...... taphylococcus aureus isolates.
@nl
P2860
P356
P1476
Systematic review and meta-ana ...... Staphylococcus aureus isolates
@en
P2093
Sebastiaan J van Hal
P2860
P304
P356
10.1128/AAC.01133-10
P407
P577
2010-11-15T00:00:00Z